New biotechnological industrial facility for the production of recombinant proteins: CIM, CIMAB and Labena


Established a new biotechnological industrial facility for the production of recombinant proteins for the treatment of cancer and neurodegenerative diseases, such as Alzheimer.

The programme is co-financed by the Slovenian Enterprise Fund and the European Union, namely from the European Fund for Regional Development. It is carried out on the basis of the Substantial Support of Fund Recipients (SME) programme from 2018 to 2023 within the framework of the Operational Programme for the Implementation of European Cohesion Policy from 2014 to 2020.